Copyright Reports & Markets. All rights reserved.

COVID-19 Impact on Global β2 Adrenoceptor Agonists Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by β2 Adrenoceptor Agonists Revenue
  • 1.4 Market Analysis by Type
    • 1.4.1 Global β2 Adrenoceptor Agonists Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Albuterol
    • 1.4.3 Terbutaline
    • 1.4.4 Salmeterol
    • 1.4.5 Formoterol
    • 1.4.6 Pirbuterol
  • 1.5 Market by Application
    • 1.5.1 Global β2 Adrenoceptor Agonists Market Share by Application: 2020 VS 2026
    • 1.5.2 Bronchial Asthma
    • 1.5.3 Asthmatic Bronchitis
    • 1.5.4 Emphysema
    • 1.5.5 Others
  • 1.6 Coronavirus Disease 2019 (Covid-19): β2 Adrenoceptor Agonists Industry Impact
    • 1.6.1 How the Covid-19 is Affecting the β2 Adrenoceptor Agonists Industry
      • 1.6.1.1 β2 Adrenoceptor Agonists Business Impact Assessment - Covid-19
      • 1.6.1.2 Supply Chain Challenges
      • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
    • 1.6.2 Market Trends and β2 Adrenoceptor Agonists Potential Opportunities in the COVID-19 Landscape
    • 1.6.3 Measures / Proposal against Covid-19
      • 1.6.3.1 Government Measures to Combat Covid-19 Impact
      • 1.6.3.2 Proposal for β2 Adrenoceptor Agonists Players to Combat Covid-19 Impact
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Global Growth Trends by Regions

  • 2.1 β2 Adrenoceptor Agonists Market Perspective (2015-2026)
  • 2.2 β2 Adrenoceptor Agonists Growth Trends by Regions
    • 2.2.1 β2 Adrenoceptor Agonists Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 β2 Adrenoceptor Agonists Historic Market Share by Regions (2015-2020)
    • 2.2.3 β2 Adrenoceptor Agonists Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 β2 Adrenoceptor Agonists Market Growth Strategy
    • 2.3.6 Primary Interviews with Key β2 Adrenoceptor Agonists Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top β2 Adrenoceptor Agonists Players by Market Size
    • 3.1.1 Global Top β2 Adrenoceptor Agonists Players by Revenue (2015-2020)
    • 3.1.2 Global β2 Adrenoceptor Agonists Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global β2 Adrenoceptor Agonists Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global β2 Adrenoceptor Agonists Market Concentration Ratio
    • 3.2.1 Global β2 Adrenoceptor Agonists Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by β2 Adrenoceptor Agonists Revenue in 2019
  • 3.3 β2 Adrenoceptor Agonists Key Players Head office and Area Served
  • 3.4 Key Players β2 Adrenoceptor Agonists Product Solution and Service
  • 3.5 Date of Enter into β2 Adrenoceptor Agonists Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global β2 Adrenoceptor Agonists Historic Market Size by Type (2015-2020)
  • 4.2 Global β2 Adrenoceptor Agonists Forecasted Market Size by Type (2021-2026)

5 β2 Adrenoceptor Agonists Breakdown Data by Application (2015-2026)

  • 5.1 Global β2 Adrenoceptor Agonists Market Size by Application (2015-2020)
  • 5.2 Global β2 Adrenoceptor Agonists Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America β2 Adrenoceptor Agonists Market Size (2015-2020)
  • 6.2 β2 Adrenoceptor Agonists Key Players in North America (2019-2020)
  • 6.3 North America β2 Adrenoceptor Agonists Market Size by Type (2015-2020)
  • 6.4 North America β2 Adrenoceptor Agonists Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe β2 Adrenoceptor Agonists Market Size (2015-2020)
  • 7.2 β2 Adrenoceptor Agonists Key Players in Europe (2019-2020)
  • 7.3 Europe β2 Adrenoceptor Agonists Market Size by Type (2015-2020)
  • 7.4 Europe β2 Adrenoceptor Agonists Market Size by Application (2015-2020)

8 China

  • 8.1 China β2 Adrenoceptor Agonists Market Size (2015-2020)
  • 8.2 β2 Adrenoceptor Agonists Key Players in China (2019-2020)
  • 8.3 China β2 Adrenoceptor Agonists Market Size by Type (2015-2020)
  • 8.4 China β2 Adrenoceptor Agonists Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan β2 Adrenoceptor Agonists Market Size (2015-2020)
  • 9.2 β2 Adrenoceptor Agonists Key Players in Japan (2019-2020)
  • 9.3 Japan β2 Adrenoceptor Agonists Market Size by Type (2015-2020)
  • 9.4 Japan β2 Adrenoceptor Agonists Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia β2 Adrenoceptor Agonists Market Size (2015-2020)
  • 10.2 β2 Adrenoceptor Agonists Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia β2 Adrenoceptor Agonists Market Size by Type (2015-2020)
  • 10.4 Southeast Asia β2 Adrenoceptor Agonists Market Size by Application (2015-2020)

11 India

  • 11.1 India β2 Adrenoceptor Agonists Market Size (2015-2020)
  • 11.2 β2 Adrenoceptor Agonists Key Players in India (2019-2020)
  • 11.3 India β2 Adrenoceptor Agonists Market Size by Type (2015-2020)
  • 11.4 India β2 Adrenoceptor Agonists Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America β2 Adrenoceptor Agonists Market Size (2015-2020)
  • 12.2 β2 Adrenoceptor Agonists Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America β2 Adrenoceptor Agonists Market Size by Type (2015-2020)
  • 12.4 Central & South America β2 Adrenoceptor Agonists Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Ivax Pharmaceuticals
    • 13.1.1 Ivax Pharmaceuticals Company Details
    • 13.1.2 Ivax Pharmaceuticals Business Overview and Its Total Revenue
    • 13.1.3 Ivax Pharmaceuticals β2 Adrenoceptor Agonists Introduction
    • 13.1.4 Ivax Pharmaceuticals Revenue in β2 Adrenoceptor Agonists Business (2015-2020))
    • 13.1.5 Ivax Pharmaceuticals Recent Development
  • 13.2 Physicians Total Care
    • 13.2.1 Physicians Total Care Company Details
    • 13.2.2 Physicians Total Care Business Overview and Its Total Revenue
    • 13.2.3 Physicians Total Care β2 Adrenoceptor Agonists Introduction
    • 13.2.4 Physicians Total Care Revenue in β2 Adrenoceptor Agonists Business (2015-2020)
    • 13.2.5 Physicians Total Care Recent Development
  • 13.3 Baxter Healthcare
    • 13.3.1 Baxter Healthcare Company Details
    • 13.3.2 Baxter Healthcare Business Overview and Its Total Revenue
    • 13.3.3 Baxter Healthcare β2 Adrenoceptor Agonists Introduction
    • 13.3.4 Baxter Healthcare Revenue in β2 Adrenoceptor Agonists Business (2015-2020)
    • 13.3.5 Baxter Healthcare Recent Development
  • 13.4 Sanofi
    • 13.4.1 Sanofi Company Details
    • 13.4.2 Sanofi Business Overview and Its Total Revenue
    • 13.4.3 Sanofi β2 Adrenoceptor Agonists Introduction
    • 13.4.4 Sanofi Revenue in β2 Adrenoceptor Agonists Business (2015-2020)
    • 13.4.5 Sanofi Recent Development
  • 13.5 Pfizer
    • 13.5.1 Pfizer Company Details
    • 13.5.2 Pfizer Business Overview and Its Total Revenue
    • 13.5.3 Pfizer β2 Adrenoceptor Agonists Introduction
    • 13.5.4 Pfizer Revenue in β2 Adrenoceptor Agonists Business (2015-2020)
    • 13.5.5 Pfizer Recent Development
  • 13.6 Bedford Laboratories
    • 13.6.1 Bedford Laboratories Company Details
    • 13.6.2 Bedford Laboratories Business Overview and Its Total Revenue
    • 13.6.3 Bedford Laboratories β2 Adrenoceptor Agonists Introduction
    • 13.6.4 Bedford Laboratories Revenue in β2 Adrenoceptor Agonists Business (2015-2020)
    • 13.6.5 Bedford Laboratories Recent Development
  • 13.7 Novartis
    • 13.7.1 Novartis Company Details
    • 13.7.2 Novartis Business Overview and Its Total Revenue
    • 13.7.3 Novartis β2 Adrenoceptor Agonists Introduction
    • 13.7.4 Novartis Revenue in β2 Adrenoceptor Agonists Business (2015-2020)
    • 13.7.5 Novartis Recent Development
  • 13.8 Sterimax
    • 13.8.1 Sterimax Company Details
    • 13.8.2 Sterimax Business Overview and Its Total Revenue
    • 13.8.3 Sterimax β2 Adrenoceptor Agonists Introduction
    • 13.8.4 Sterimax Revenue in β2 Adrenoceptor Agonists Business (2015-2020)
    • 13.8.5 Sterimax Recent Development
  • 13.9 Teligent
    • 13.9.1 Teligent Company Details
    • 13.9.2 Teligent Business Overview and Its Total Revenue
    • 13.9.3 Teligent β2 Adrenoceptor Agonists Introduction
    • 13.9.4 Teligent Revenue in β2 Adrenoceptor Agonists Business (2015-2020)
    • 13.9.5 Teligent Recent Development
  • 13.10 AstraZeneca
    • 13.10.1 AstraZeneca Company Details
    • 13.10.2 AstraZeneca Business Overview and Its Total Revenue
    • 13.10.3 AstraZeneca β2 Adrenoceptor Agonists Introduction
    • 13.10.4 AstraZeneca Revenue in β2 Adrenoceptor Agonists Business (2015-2020)
    • 13.10.5 AstraZeneca Recent Development
  • 13.11 Hikma Pharmaceuticals
    • 10.11.1 Hikma Pharmaceuticals Company Details
    • 10.11.2 Hikma Pharmaceuticals Business Overview and Its Total Revenue
    • 10.11.3 Hikma Pharmaceuticals β2 Adrenoceptor Agonists Introduction
    • 10.11.4 Hikma Pharmaceuticals Revenue in β2 Adrenoceptor Agonists Business (2015-2020)
    • 10.11.5 Hikma Pharmaceuticals Recent Development
  • 13.12 Av Kare
    • 10.12.1 Av Kare Company Details
    • 10.12.2 Av Kare Business Overview and Its Total Revenue
    • 10.12.3 Av Kare β2 Adrenoceptor Agonists Introduction
    • 10.12.4 Av Kare Revenue in β2 Adrenoceptor Agonists Business (2015-2020)
    • 10.12.5 Av Kare Recent Development
  • 13.13 Impax Laboratories
    • 10.13.1 Impax Laboratories Company Details
    • 10.13.2 Impax Laboratories Business Overview and Its Total Revenue
    • 10.13.3 Impax Laboratories β2 Adrenoceptor Agonists Introduction
    • 10.13.4 Impax Laboratories Revenue in β2 Adrenoceptor Agonists Business (2015-2020)
    • 10.13.5 Impax Laboratories Recent Development
  • 13.14 PD-Rx Pharmaceuticals
    • 10.14.1 PD-Rx Pharmaceuticals Company Details
    • 10.14.2 PD-Rx Pharmaceuticals Business Overview and Its Total Revenue
    • 10.14.3 PD-Rx Pharmaceuticals β2 Adrenoceptor Agonists Introduction
    • 10.14.4 PD-Rx Pharmaceuticals Revenue in β2 Adrenoceptor Agonists Business (2015-2020)
    • 10.14.5 PD-Rx Pharmaceuticals Recent Development
  • 13.15 Athenex Pharmaceutical Division
    • 10.15.1 Athenex Pharmaceutical Division Company Details
    • 10.15.2 Athenex Pharmaceutical Division Business Overview and Its Total Revenue
    • 10.15.3 Athenex Pharmaceutical Division β2 Adrenoceptor Agonists Introduction
    • 10.15.4 Athenex Pharmaceutical Division Revenue in β2 Adrenoceptor Agonists Business (2015-2020)
    • 10.15.5 Athenex Pharmaceutical Division Recent Development
  • 13.16 Teva
    • 10.16.1 Teva Company Details
    • 10.16.2 Teva Business Overview and Its Total Revenue
    • 10.16.3 Teva β2 Adrenoceptor Agonists Introduction
    • 10.16.4 Teva Revenue in β2 Adrenoceptor Agonists Business (2015-2020)
    • 10.16.5 Teva Recent Development
  • 13.17 Marlex Pharmaceuticals
    • 10.17.1 Marlex Pharmaceuticals Company Details
    • 10.17.2 Marlex Pharmaceuticals Business Overview and Its Total Revenue
    • 10.17.3 Marlex Pharmaceuticals β2 Adrenoceptor Agonists Introduction
    • 10.17.4 Marlex Pharmaceuticals Revenue in β2 Adrenoceptor Agonists Business (2015-2020)
    • 10.17.5 Marlex Pharmaceuticals Recent Development
  • 13.18 Lannett Company
    • 10.18.1 Lannett Company Company Details
    • 10.18.2 Lannett Company Business Overview and Its Total Revenue
    • 10.18.3 Lannett Company β2 Adrenoceptor Agonists Introduction
    • 10.18.4 Lannett Company Revenue in β2 Adrenoceptor Agonists Business (2015-2020)
    • 10.18.5 Lannett Company Recent Development
  • 13.19 West-Ward Pharmaceuticals
    • 10.19.1 West-Ward Pharmaceuticals Company Details
    • 10.19.2 West-Ward Pharmaceuticals Business Overview and Its Total Revenue
    • 10.19.3 West-Ward Pharmaceuticals β2 Adrenoceptor Agonists Introduction
    • 10.19.4 West-Ward Pharmaceuticals Revenue in β2 Adrenoceptor Agonists Business (2015-2020)
    • 10.19.5 West-Ward Pharmaceuticals Recent Development
  • 13.20 United Biomedical
    • 10.20.1 United Biomedical Company Details
    • 10.20.2 United Biomedical Business Overview and Its Total Revenue
    • 10.20.3 United Biomedical β2 Adrenoceptor Agonists Introduction
    • 10.20.4 United Biomedical Revenue in β2 Adrenoceptor Agonists Business (2015-2020)
    • 10.20.5 United Biomedical Recent Development
  • 13.21 Merck
    • 10.21.1 Merck Company Details
    • 10.21.2 Merck Business Overview and Its Total Revenue
    • 10.21.3 Merck β2 Adrenoceptor Agonists Introduction
    • 10.21.4 Merck Revenue in β2 Adrenoceptor Agonists Business (2015-2020)
    • 10.21.5 Merck Recent Development
  • 13.22 Mylan
    • 10.22.1 Mylan Company Details
    • 10.22.2 Mylan Business Overview and Its Total Revenue
    • 10.22.3 Mylan β2 Adrenoceptor Agonists Introduction
    • 10.22.4 Mylan Revenue in β2 Adrenoceptor Agonists Business (2015-2020)
    • 10.22.5 Mylan Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    This report focuses on the global β2 Adrenoceptor Agonists status, future forecast, growth opportunity, key market and key players. The study objectives are to present the β2 Adrenoceptor Agonists development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

    The key players covered in this study
    Ivax Pharmaceuticals 
    Physicians Total Care
    Baxter Healthcare 
    Sanofi
    Pfizer
    Bedford Laboratories
    Novartis
    Sterimax
    Teligent
    AstraZeneca
    Hikma Pharmaceuticals
    Av Kare
    Impax Laboratories
    PD-Rx Pharmaceuticals
    Athenex Pharmaceutical Division
    Teva
    Marlex Pharmaceuticals
    Lannett Company
    West-Ward Pharmaceuticals
    United Biomedical
    Merck
    Mylan

    Market segment by Type, the product can be split into
    Albuterol
    Terbutaline
    Salmeterol
    Formoterol
    Pirbuterol
    Market segment by Application, split into
    Bronchial Asthma
    Asthmatic Bronchitis
    Emphysema
    Others

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    The study objectives of this report are:
    To analyze global β2 Adrenoceptor Agonists status, future forecast, growth opportunity, key market and key players.
    To present the β2 Adrenoceptor Agonists development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
    To strategically profile the key players and comprehensively analyze their development plan and strategies.
    To define, describe and forecast the market by type, market and key regions.

    In this study, the years considered to estimate the market size of β2 Adrenoceptor Agonists are as follows:
    History Year: 2015-2019
    Base Year: 2019
    Estimated Year: 2020
    Forecast Year 2020 to 2026
    For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

    Buy now